This is a phase 1b/2a study that evaluates the safety and efficacy of Pexa-Vec, a modified vaccinia virus, when used alongside cemiplimab, an anti-PD-1 monoclonal antibody from Regeneron Pharmaceuticals Inc.

Immuneering Corporation, a clinical-stage oncology firm, has initiated a Phase 1/2a clinical trial for IMM-6-415, a novel Deep Cyclic Inhibitor (DCI) targeting the MAPK pathway.

AFM24 Clinical Trial Updates: In a Phase 1/2a study combining AFM24 with atezolizumab for non-small cell lung cancer (NSCLC) patients with EGFR-wildtype.

The preliminary safety findings from a Phase 1B clinical trial involving VRON-0200, a groundbreaking immunotherapy for chronic hepatitis B (HBV), were recently highlighted.

In a recent phase 1b clinical trial, patients received multiple injections of a novel immunotherapy, CAN-3110, developed by Candel Therapeutics.

MapLight Therapeutics has initiated a Phase 1 clinical trial for ML-007/PAC, a novel combination therapy aimed at treating schizophrenia and Alzheimer's disease psychosis.

Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have announced an exclusive license agreement for the development and commercialization of Xilio's tumor-activated IL-12 program, XTX301.

Aeovian Pharmaceuticals, focused on creating innovative therapeutics that target the mTORC1 pathway, has initiated its Phase 1 clinical trial for AV078.

Aurion Biotech has commenced a Phase 1/2 clinical trial for AURN001, a novel cell therapy addressing corneal edema due to endothelial dysfunction.

Neurocrine Biosciences has launched a Phase 1 clinical trial for NBI-1065890, an experimental oral medication.

Pheast Therapeutics revealed the initial showcasing of preclinical data for PHST001, an anti-CD24 antibody drug candidate.

May 17th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.